首页> 美国卫生研究院文献>Journal of Clinical Microbiology >In Vitro Activities of the New Antifungal Drug Eberconazole and Three Other Topical Agents against 200 Strains of Dermatophytes
【2h】

In Vitro Activities of the New Antifungal Drug Eberconazole and Three Other Topical Agents against 200 Strains of Dermatophytes

机译:新抗真菌药埃伯康唑和其他三种局部用药对200株皮肤癣菌的体外活性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

We have compared the in vitro activity of the new antifungal drug eberconazole with those of three other topical antifungal agents, clotrimazole, ketoconazole, and miconazole, against 200 strains of dermatophytes. MICs were determined by a microdilution method with optimal conditions determined in a previous study (an inoculum of 104 CFU/ml, an incubation temperature of 28°C, an incubation period of 7 days, and a MIC endpoint of 100% inhibition of growth). In general, the four drugs tested showed low MICs. However, eberconazole was more active (P < 0.05) than the other three drugs against the majority of the species tested. Eberconazole represents an advantageous alternative for dermatophytoses where a topical therapy is required.
机译:我们已经比较了新的抗真菌药埃伯康唑与其他三种局部抗真菌药克霉唑,酮康唑和咪康唑对200株皮肤癣菌的体外活性。通过微量稀释法确定MIC,并在先前的研究中确定了最佳条件(接种量为10 4 CFU / ml,孵育温度为28°C,孵育时间为7天,并且MIC 100%抑制生长的终点)。通常,所测试的四种药物的MIC较低。但是,依伯康唑对大多数被测物种的活性高于其他三种药物(P <0.05)。埃贝康唑是需要局部治疗的皮肤癣菌的一种有利替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号